IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 2661-22 C# M# 0410

CRAPO et al

Serial No. 10/051,367

Filed: January 22, 2002

Title: CANCER THERAPY

Assistant Commissioner for Paterite Washington, DC 20231

Group Art Unit: Examiner:

0

Date: July 3, 2002

*/

Sir:

INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

minus highest number

Fees are attached as calculated below: Total effective claims after amendment

previously paid for 20 (at least 20) = 0 x \$ 18.00	\$	0.00
Independent claims after amendment previously paid for 3 (at least 3) = 0 minus highest number 0 \mathbf{x} \$ 84.00	\$	0.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)	\$	0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)	\$	0.00
Terminal disclaimer enclosed, add \$ 110.00	\$	0.00
☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) ☐ Please enter the previously unentered , filed ☐ Submission attached	\$	0.00
Subtotal	\$	0.00
If "small entity," then enter half (1/2) of subtotal and subtract Applicant claims "small entity" status. Statement filed herewith	-\$	0.00
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$	0.00
Assignment Recording Fee (\$40.00)	\$	0.00
Other:		0.00
TOTAL FEE ENCLOSED	\$	0.00

The Commissioner is hereby authorized to charge any <u>deficiency</u>, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

MJW:tat

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

Signature:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

CRAPO et al Atty. Ref.: 2661-22

Serial No.: 10/051,367 Group Art Unit:

Filed: January 22, 2002 Examiner:

For: CANCER THERAPY

July 3, 2002

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

Attached is Form PTO-1449 listing the enclosed documents.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

Contingent Request Under Rule 97(c): Should a first action on the merits have been issued on the same day or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite Rule 17(p) fee to our

CRAPO et al -- rial No.: 10/051,367

Deposit Account No. 14-1140 (2661-22) and proceed to consider this IDS.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

Mary J. Wilson

Reg. No. 32,955

MJW:tat

1100 North Glebe Road

8th Floor

Arlington, Virginia 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include

*Examiner

copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)